Get Started
HBV Curricula
Step 1
These independent CME/CE activities are supported by an educational grant from Bristol-Myers Squibb.

Chronic Hepatitis B Management III
Bridging Cultural Differences to Improve HBV Treatment
in Asian and Other Diverse Communities
  1. Course List
faculty image
Adrian M. Di Bisceglie, MD, FACP
  • Acting Chairman, Internal Medicine
  • Chief of Hepatology
  • Saint Louis University School of Medicine
  • St. Louis, Missouri
  • faculty image
    Robert G. Gish, MD
  • Medical Director
  • Liver Transplant Program
  • Chief, Division of Hepatology and Complex GI
  • California Pacific Medical Center
  • San Francisco, California
  • Adrian M. Di Bisceglie, MD, FACP, and Robert G. Gish, MD, co-chair this free, yearlong CME/CE program offering the latest information on chronic hepatitis B virus (HBV) infection. Curriculum topics include screening, genotyping, testing for antiviral-resistance mutations, treatment guidelines (updates from AASLD, EASL, and DDW), current and emerging HBV treatment options, consolidation therapy, HIV/HCV coinfection, cirrhosis, and cultural/communications barriers to diagnosis and treatment. Learn more and enroll today!
  • Understand the impact of cultural differences in the management of HBV infection, with focus on the Asian and Pacific Islander community.
  • Assess the role of HBV DNA and other markers in determining when to treat and treatment selection in HBV-infected patients with diverse ethnic backgrounds, and in evaluating on-treatment response to therapy to improve patient outcomes.
  • Formulate anti-HBV treatment strategies, considering safety, efficacy, endpoints, and resistance patterns of currently available and emerging antiviral agents as well as cultural differences among patients, to improve response rates in patients with HBV infection.
  • Integrate prescribing and monitoring strategies to help prevent or reduce the emergence of resistance into individualized anti-HBV treatment plans for infected patients.
    • AASLD, Keeffe, and APASL HBV Treatment Guidelines
    • Treatments
      • (Peg)interferon
      • Oral Nucleosides/Nucleotides: Lamivudine, Adefovir, Entecavir, Telbivudine
      • Investigational Drugs: Emtricitabine, Tenofovir, Clevudine
      • Combination Therapy
    • Treatment Endpoints and Duration
    • Monitoring for Treatment Response
    • AASLD, Keeffe, and APASL Hepatitis B virus Treatment Guidelines
    • HBV Basics — including virology and genotype
    • Assessing At-Risk Individuals for HBV - Special Populations
    • Screening and Diagnosis in the Asian Community
    • Chronic HBV Disease Burden
    • HBV Treatment Options and Strategies
    • HBV Treatment Resistance - Detection and Management

    Target Audience

    This activity is designed for gastroenterologists, hepatologists, and other clinicians who care for patients with hepatitis B infection or those at increased risk for acquiring the infection.


    Activity Goal

    The goal of this CME/CE activity is to examine the latest information about treating chronic hepatitis B virus (HBV) infection, taking into account the most current guidelines, recent FDA approvals, and new data, in order to effectively suppress viral replication.